Ptc Therapeutics stock hits 52-week low at $58.57
PTC Therapeutics Inc. stock sank to a 52-week low of $58.57, just a penny shy of its yearly low of $58.80. This marks a troubling 20.7% decline for the year for the biopharmaceutical company, which is valued at $4.93 billion. The business reported a $1.16 billion revenue for the past year, but it still faces hurdles despite boasting a robust gross profit margin of 55.18%.
According to InvestingPro analysis, the stock seems underpriced at present, and experts anticipate the firm will turn profitable again this year. Investors can delve into more information via InvestingPro’s detailed Pro Research Report, which simplifies intricate financial data into practical insights for PTCT and over 1,400 other US equities.
In a separate development, PTC Therapeutics disclosed a revenue of $357.8 million in the third quarter of 2026, exceeding Wall Street’s forecast of $304.05 million. However, the firm reported a loss of $0.62 per share, sharply contrasting the expected profit of $0.30 per share. This revenue surge was fueled by robust demand for SEPHIENCE and royalty income from Evrysdi.
Truist Securities maintained a Hold rating on PTC Therapeutics with a price target of $62.00 after examining the quarterly results. Management expressed optimism about the SEPHIENCE launch transitioning into a more mature growth phase. These recent events have piqued investor interest, as they grapple with the company's strong sales against its earnings shortfall. This report was produced with AI assistance and edited by a human.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.